Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: Identification of 1p31-32 deletion as a prognostic factor in myeloma

W. J. Chng, Morie Gertz, T. H. Chung, S. Van Wier, J. J. Keats, A. Baker, Peter Leif Bergsagel, J. Carpten, Rafael Fonseca

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

In this study, we correlated array-comparative genomic hybridization- defined abnormalities with survival in two different cohorts of patients treated with therapy based on high-dose melphalan with autologous stem-cell transplantation (64 from the Mayo Clinic and 67 from the University of Arkansas Medical School) and identified that several regions of genomic gains and losses were significantly associated with poorer survival. Three noncontiguous survival relevant regions covering 1p31-33 and two noncontiguous regions covering 20p12.3-12.1 were common between the two datasets. The prognostic relevance of these hotspots was validated in an independent cohort using fluorescent in situ hybridization, which showed that 1p31-32 loss is significantly associated with shorter survival (24.5 months versus 40 months, log-rank P-value0.01), whereas 20p12 loss has a trend toward shorter survival (26.3 months versus 40 months, log-rank P-value0.06). On multivariate analysis, 1p31-32 loss is an independent prognostic factor. On further analysis, the prognostic impact of 1p31-32 loss is due to shortening of post-relapse survival as there is no impact on complete response rates and progression-free survival.

Original languageEnglish (US)
Pages (from-to)833-842
Number of pages10
JournalLeukemia
Volume24
Issue number4
DOIs
StatePublished - Apr 2010

Fingerprint

Comparative Genomic Hybridization
Survival
Melphalan
Stem Cell Transplantation
Fluorescence In Situ Hybridization
Medical Schools
Disease-Free Survival
Multivariate Analysis
Recurrence

Keywords

  • Array-comparative genomic hybridization
  • Chromosome 1p
  • Prognosis

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival : Identification of 1p31-32 deletion as a prognostic factor in myeloma. / Chng, W. J.; Gertz, Morie; Chung, T. H.; Van Wier, S.; Keats, J. J.; Baker, A.; Bergsagel, Peter Leif; Carpten, J.; Fonseca, Rafael.

In: Leukemia, Vol. 24, No. 4, 04.2010, p. 833-842.

Research output: Contribution to journalArticle

@article{a966d8203e384312986e592437802b30,
title = "Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: Identification of 1p31-32 deletion as a prognostic factor in myeloma",
abstract = "In this study, we correlated array-comparative genomic hybridization- defined abnormalities with survival in two different cohorts of patients treated with therapy based on high-dose melphalan with autologous stem-cell transplantation (64 from the Mayo Clinic and 67 from the University of Arkansas Medical School) and identified that several regions of genomic gains and losses were significantly associated with poorer survival. Three noncontiguous survival relevant regions covering 1p31-33 and two noncontiguous regions covering 20p12.3-12.1 were common between the two datasets. The prognostic relevance of these hotspots was validated in an independent cohort using fluorescent in situ hybridization, which showed that 1p31-32 loss is significantly associated with shorter survival (24.5 months versus 40 months, log-rank P-value0.01), whereas 20p12 loss has a trend toward shorter survival (26.3 months versus 40 months, log-rank P-value0.06). On multivariate analysis, 1p31-32 loss is an independent prognostic factor. On further analysis, the prognostic impact of 1p31-32 loss is due to shortening of post-relapse survival as there is no impact on complete response rates and progression-free survival.",
keywords = "Array-comparative genomic hybridization, Chromosome 1p, Prognosis",
author = "Chng, {W. J.} and Morie Gertz and Chung, {T. H.} and {Van Wier}, S. and Keats, {J. J.} and A. Baker and Bergsagel, {Peter Leif} and J. Carpten and Rafael Fonseca",
year = "2010",
month = "4",
doi = "10.1038/leu.2010.21",
language = "English (US)",
volume = "24",
pages = "833--842",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival

T2 - Identification of 1p31-32 deletion as a prognostic factor in myeloma

AU - Chng, W. J.

AU - Gertz, Morie

AU - Chung, T. H.

AU - Van Wier, S.

AU - Keats, J. J.

AU - Baker, A.

AU - Bergsagel, Peter Leif

AU - Carpten, J.

AU - Fonseca, Rafael

PY - 2010/4

Y1 - 2010/4

N2 - In this study, we correlated array-comparative genomic hybridization- defined abnormalities with survival in two different cohorts of patients treated with therapy based on high-dose melphalan with autologous stem-cell transplantation (64 from the Mayo Clinic and 67 from the University of Arkansas Medical School) and identified that several regions of genomic gains and losses were significantly associated with poorer survival. Three noncontiguous survival relevant regions covering 1p31-33 and two noncontiguous regions covering 20p12.3-12.1 were common between the two datasets. The prognostic relevance of these hotspots was validated in an independent cohort using fluorescent in situ hybridization, which showed that 1p31-32 loss is significantly associated with shorter survival (24.5 months versus 40 months, log-rank P-value0.01), whereas 20p12 loss has a trend toward shorter survival (26.3 months versus 40 months, log-rank P-value0.06). On multivariate analysis, 1p31-32 loss is an independent prognostic factor. On further analysis, the prognostic impact of 1p31-32 loss is due to shortening of post-relapse survival as there is no impact on complete response rates and progression-free survival.

AB - In this study, we correlated array-comparative genomic hybridization- defined abnormalities with survival in two different cohorts of patients treated with therapy based on high-dose melphalan with autologous stem-cell transplantation (64 from the Mayo Clinic and 67 from the University of Arkansas Medical School) and identified that several regions of genomic gains and losses were significantly associated with poorer survival. Three noncontiguous survival relevant regions covering 1p31-33 and two noncontiguous regions covering 20p12.3-12.1 were common between the two datasets. The prognostic relevance of these hotspots was validated in an independent cohort using fluorescent in situ hybridization, which showed that 1p31-32 loss is significantly associated with shorter survival (24.5 months versus 40 months, log-rank P-value0.01), whereas 20p12 loss has a trend toward shorter survival (26.3 months versus 40 months, log-rank P-value0.06). On multivariate analysis, 1p31-32 loss is an independent prognostic factor. On further analysis, the prognostic impact of 1p31-32 loss is due to shortening of post-relapse survival as there is no impact on complete response rates and progression-free survival.

KW - Array-comparative genomic hybridization

KW - Chromosome 1p

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=77950949924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950949924&partnerID=8YFLogxK

U2 - 10.1038/leu.2010.21

DO - 10.1038/leu.2010.21

M3 - Article

C2 - 20220778

AN - SCOPUS:77950949924

VL - 24

SP - 833

EP - 842

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 4

ER -